Renin–angiotensin system and neprilysin
Keyword(s):
The advent of drugs able to modulate the renin–angiotensin system (RAS), and more recently the neprilysin inhibitor sacubitril in combination with a RAS blocker, has improved the outcome of many cardiovascular and renal conditions. In particular, heart failure, post-myocardial infarction, and hypertension are the cardiovascular clinical syndromes in which RAS inhibition (and in heart failure, in combination with neprilysin inhibition) has greatly improved morbidity and mortality. This chapter aims to provide an appraisal of RAS and neprilysin inhibitors regarding their pharmacological properties with respect to mechanism(s) of action, pharmacokinetics, monitoring, adverse effects, and drug interactions.
2019 ◽
Vol 73
(9)
◽
pp. 1020
2020 ◽
Vol 76
(9)
◽
pp. 1034-1048
◽
1999 ◽
Vol 277
(5)
◽
pp. H1786-H1792
◽
2005 ◽
Vol 3
(4)
◽
pp. 717-732
◽
2004 ◽
Vol 263
(1/2)
◽
pp. 11-20
◽
Keyword(s):
2007 ◽
Vol 79
(2)
◽
pp. 250-259
◽
2004 ◽
Vol 110
(20)
◽
pp. 3281-3288
◽